Intellia therapeutics Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Intellia therapeutics Contact Number

Contact Intellia Therapeutics

5 hours ago Intelliatx.com Get All

Patients and Medical Affairs Contact. Clinical trial A test of a new medical treatment or procedure in human volunteers with the purpose of evaluating a medical, surgical or behavioral intervention. Clinical trials typically follow preclinical (non-human) studies and are the primary way that clinical researchers and regulatory agencies evaluate whether a new treatment is safe and effective in

Estimated Reading Time: 50 secs

Website: https://www.intelliatx.com/contact/

Category: Contact SupportShow more

Intellia Therapeutics Crunchbase Company Profile & Funding

1 hours ago Crunchbase.com Get All

(857) 285-6200

Contact Email [email protected] Phone Number (857) 285-6200. Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments. It can positively transform the lives of people living with severe and life-threatening diseases. IIntellia holds exclusive access to one of the most comprehensive intellectual

Founded: 2014
Founders: Dr Rachel Haurwitz, Nessan Bermingham, Erik J. Sontheimer Ph.D.

Website: https://www.crunchbase.com/organization/intellia-therapeutics

Category: Contact NumberShow more

Home Intellia Therapeutics

7 hours ago Intelliatx.com Get All

Using CRISPR/Cas9 technology, Intellia Therapeutics is developing revolutionary genome editing therapies to cure genetic diseases with simple, targeted treatments. Full-Spectrum Blog Contact

Website: https://www.intelliatx.com/

Category: Home PhoneShow more

Intellia Therapeutics, Inc. Company Profile Cambridge

9 hours ago Dnb.com Get All

(857) 285-6200

Intellia Therapeutics, Inc. is located in Cambridge, MA, United States and is part of the Scientific Research and Development Services Industry. Intellia Therapeutics, Inc. has 104 total employees across all of its locations and generates $57.99 million in sales (USD). There are 2 companies in the Intellia Therapeutics, Inc. corporate family.

Employees: 104
Phone: (857) 285-6200
Location: 40 Erie St, Cambridge, 02139-4254, MA

Website: https://www.dnb.com/business-directory/company-profiles.intellia_therapeutics_inc.ce3e77cc42ebe1cd6fcadda9eb69e773.html

Category: Contact NumberShow more

Jose Rivera's email & phone Intellia Therapeutics, Inc

Just Now Rocketreach.co Get All

General Counsel & Chief Talent Officer @ Intellia Therapeutics, Inc. VP, Chief Ethics & Compliance Officer @ AbbVie Inc. DVP & Associate General Counsel - Intellectual Property Group @ Abbott Laboratories Education: 1987 - 1990 JD in Law @ Harvard Law School

Website: https://rocketreach.co/jose-e-rivera-email_3290300

Category: Phone NumberShow more

Intellia Therapeutics Overview, News & Competitors

2 hours ago Zoominfo.com Get All

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter …

Website: https://www.zoominfo.com/c/intellia-therapeutics-inc/367623611

Category: Contact NumberShow more

Leadership Intellia Therapeutics

7 hours ago Intelliatx.com Get All

In his role at Intellia, he will lead the Company’s corporate communications activities, including investor and media relations. Before joining Intellia in July 2021, Ian served as Senior Vice President, Investor and Public Relations at Karyopharm Therapeutics, an oncology-focused pharmaceutical company.

Website: https://www.intelliatx.com/overview/leadership/

Category: Contact NumberShow more

Clinical Trials Intellia Intellia Therapeutics

8 hours ago Intelliatx.com Get All

Clinical Trials. Intellia Therapeutics is committed to developing genome editing. X Also called gene editing. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Genome editing uses systems to make the DNA change inside the cell.

Website: https://www.intelliatx.com/our-commitment/clinical-trials/

Category: Contact NumberShow more

Regeneron and Intellia Therapeutics Expand Collaboration

Just Now Investor.regeneron.com Get All

914.847.3482

Regeneron IR Contact: Mark Hudson 914.847.3482 [email protected] Regeneron Media Contact: Alexandra Bowie 914.847.3407 [email protected] Intellia Media Contact: Jennifer Mound Smoter 224.804.4462 [email protected] Intellia IR Contact: Lina Li 857.706.1162 [email protected]

Website: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop

Category: Contact NumberShow more

Nick Marcantonio Portfoli.. Intellia Therapeutics

4 hours ago Zoominfo.com Get All

View Nick Marcantonio's business profile as Portfolio Vice President, Strategy at Intellia Therapeutics. Find contact's direct phone number, email address, work history, and more.

Website: https://www.zoominfo.com/p/Nick-Marcantonio/5360718252

Category: Contact NumberShow more

Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call

6 hours ago Msn.com Get All

10 stocks we like better than Intellia Therapeutics. dose with a very limited number of dosing cohorts. investigation sites and our development team is in daily contact with them as that

Website: https://www.msn.com/en-us/money/companies/intellia-therapeutics-inc-ntla-q2-2021-earnings-call-transcript/ar-AAN26nW

Category: Contact NumberShow more

Opening a New Era of Medicine Intellia Therapeutics

1 hours ago Intelliatx.com Get All

After a 40-Year Career, I’m Back at a New Beginning. This week, we entered a new era of medicine. Our team at Intellia Therapeutics announced the first clinical data in history suggesting that we can harness the genome editing technology CRISPR to precisely edit target cells within the body.

Website: https://www.intelliatx.com/full-spectrum/opening-a-new-era-of-medicine/

Category: Contact NumberShow more

Intellia Therapeutics Company Profile Office Locations

2 hours ago Craft.co Get All

Intellia Therapeutics has 270 employees at their 1 location and $57.99 M in annual revenue in FY 2020. See insights on Intellia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Website: https://craft.co/intellia-therapeutics-714

Category: Contact NumberShow more

Intellia Therapeutics (NTLA) Company Profile & Overview

6 hours ago Stockanalysis.com Get All

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment

Website: https://stockanalysis.com/stocks/ntla/company/

Category: Contact NumberShow more

Intellia Therapeutics Congratulates CoFounder Jennifer

3 hours ago Ir.intelliatx.com Get All

CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Dr. Doudna shared the award with her research collaborator, Dr. Emmanuelle Charpentier.This is the first time two women …

Website: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-congratulates-co-founder-jennifer-doudna

Category: Contact NumberShow more

Intellia Therapeutics Receives Grant to Develop Curative

5 hours ago Ir.intelliatx.com Get All

Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients. CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that it has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease (SCD) treatments …

Website: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-receives-grant-develop-curative-crisprcas9

Category: Contact NumberShow more

Events & Presentations Intellia Therapeutics

6 hours ago Ir.intelliatx.com Get All

The Investor Relations website contains information about Intellia Therapeutics's business for stockholders, potential investors, and financial analysts.

Website: https://ir.intelliatx.com/events-and-presentations/upcoming-events

Category: Contact NumberShow more

Intellia Therapeutics FierceBiotech

6 hours ago Fiercebiotech.com Get All

Intellia Therapeutics. The scoop: The fledgling Intellia has gone further and faster in the past 10 months than most biotechs get in several years. It was born with an investment assist from

Website: https://www.fiercebiotech.com/special-report/intellia-therapeutics

Category: Tech SupportShow more

Intellia Therapeutics Announces Patent for CRISPR/Cas

4 hours ago Ir.intelliatx.com Get All

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course.

Website: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-patent-crisprcas-genome-editing

Category: Contact NumberShow more

Intellia Therapeutics Announces First Quarter 2020

1 hours ago Ir.intelliatx.com Get All

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the first quarter ended March 31, 2020.

Website: https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-quarter-2020-financial

Category: Contact NumberShow more

Intellia Therapeutics Wikipedia

1 hours ago En.wikipedia.org Get All

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University).The company has partnerships with Novartis and Regeneron. History. Intellia Therapeutics was founded in May 2014 to develop

1. Cambridge, MA
Founded: 2014
2. Biotherapeutics
Number of employees: 312 (2021)

Website: https://en.wikipedia.org/wiki/Intellia_Therapeutics

Category: Contact NumberShow more

David Cooke Senior Direct.. Intellia Therapeutics

9 hours ago Zoominfo.com Get All

View David Cooke's business profile as Senior Director, Clinical Program Management at Intellia Therapeutics. Find contact's direct phone number, email address, work history, and more.

Website: https://www.zoominfo.com/p/David-Cooke/2297586536

Category: Contact NumberShow more

Intellia Therapeutics: Number of Employees 20152021

8 hours ago Macrotrends.net Get All

Dividend Yield History. Number of Employees. Interactive chart of Intellia Therapeutics (NTLA) annual worldwide employee count from 2015 to 2021. Intellia Therapeutics total number of employees in 2020 was 312, a 15.56% increase from 2019. Intellia Therapeutics total number of employees in 2019 was 270, a 27.96% increase from 2018.

Website: https://www.macrotrends.net/stocks/charts/NTLA/intellia-therapeutics/number-of-employees

Category: Contact NumberShow more

Intellia Therapeutics Funding, Financials, Valuation

Just Now Crunchbase.com Get All

Intellia Therapeutics has raised a total of $775M in funding over 3 rounds. Their latest funding was raised on Jun 30, 2021 from a Post-IPO Equity round. Intellia Therapeutics is registered under the ticker NASDAQ:NTLA . Their stock opened with $22.00 in its May 6, 2016 IPO.

Website: https://www.crunchbase.com/organization/intellia-therapeutics/company_financials

Category: Contact NumberShow more

Intellia Therapeutics YouTube

3 hours ago Youtube.com Get All

Jenn King, Ph.D., SVP, Business Development Cambridge, MA (NASDAQ: NTLA) Intellia Therapeutics is a leading genome editing company focused on the development

Website: https://www.youtube.com/watch?v=XOZB-BJnsOE

Category: Contact NumberShow more

Regeneron and Intellia Therapeutics Announce Collaboration

5 hours ago Investor.regeneron.com Get All

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the …

Website: https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-announce-collaboration/

Category: Contact NumberShow more

20 Things You Didn't Know About Intellia Therapeutics

3 hours ago Moneyinc.com Get All

1. Intellia Therapeutics chief technology is CRISPR. According to Wikipedia, Intellia Therapeutics arose from the efforts of a group of researchers at the University of California, Berkely.
2. Intellia Therapeutics partners with other biotechs. Intellia is embarking on research and discoveries in the biopharmaceutical industry with broad implications.
3. Intellia Therapeutics is still a young company. Intellia Therapeutics hasn’t been in operation for that long. It was officially launched in 2014. The company is entering its seventh year of business.
4. Intellia Therapeutics is a versatile biotech organization. According to Crunchbase, Intellia Therapeutics falls under five different industry categories because of the scope of its reach.
5. Intellia Therapeutics is a woman-founded and led the company. Intellia Therapeutics ranks highly on the diversity scale. The business was founded by women in 2014, It is in the diversity spotlight in the United States as such, which is encouraging as there has been a movement to bring more women into the science sector of business.
6. Intellia Therapeutics has seven founders. The biotech firm is the creation of collaboration among seven professionals in the biotech, medical, business, and healthcare arenas.
7. Intellia Therapeutics has a 16 member executive leadership team. The leadership team for Intellia Therapeutics is large, comprised of 16 members. Derrick Rossi is a founder.
8. Intellia Therapeutics has a 3 member board of directors. The board of directors for Intellia Therapeutics is remarkably small with just three members.
9. Intellia’s website alone uses complex technology. Intellia Therapeutics maintains an official webpage that describes the functions of the company and provides relevant news and information.
10. The overhead expenses are high for Intellia Therapeutics. Intellia Therapeutics invests a great deal into its IT and website technology. The average cost of software and technology products to keep the website running is an estimated $660.5 thousand per year.

Website: https://moneyinc.com/intellia-therapeutics/

Category: Contact NumberShow more

Shares in Intellia Therapeutics, Inc. (NTLA) 200.94 % up

6 hours ago Marketingsentinel.com Get All

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has a beta value of 2.15 and has seen 2,925,569 shares traded in the last trading session. The company, currently valued at $11.16 Billion, closed the last trade at $163.71 per share which meant it lost -$7.94 on the day or …

Website: https://marketingsentinel.com/2021/07/06/shares-in-intellia-therapeutics-inc-ntla-200-94-up-ytd/

Category: Contact NumberShow more

Intellia Therapeutics, Inc. (NTLA) Expected to Beat

5 hours ago Finance.yahoo.com Get All

For the last reported quarter, it was expected that Intellia Therapeutics, Inc. Would post a loss of $0.66 per share when it actually produced a loss of $0.69, delivering a surprise of -4.55%

Website: https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-expected-190507234.html

Category: Contact NumberShow more

Can Intellia Therapeutics Inc. (NTLA) Future Potential Be

5 hours ago Marketingsentinel.com Get All

Investors are also buoyed by the number of investors in a company, with Intellia Therapeutics Inc. having a total of 375 institutions that hold shares in the company. The top two institutional holders are ARK Investment Management, LLC …

Website: https://marketingsentinel.com/2021/07/28/can-intellia-therapeutics-inc-ntla-future-potential-be-undermined-by-current-price-volatility/

Category: Contact NumberShow more

Intellia Therapeutics Presents Preclinical Proof of

3 hours ago Biospace.com Get All

Learn more about Intellia and CRISPR/Cas9 at intelliatx.com. Follow us on Twitter @intelliatweets. Forward-Looking Statements This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995.

Website: https://www.biospace.com/article/releases/intellia-therapeutics-presents-preclinical-proof-of-concept-for-crispr-based-in-vivo-editing-of-bone-marrow-at-keystone-esymposium/

Category: Contact NumberShow more

Intellia Therapeutics Reaches Analyst Target Price Nasdaq

3 hours ago Nasdaq.com Get All

In recent trading, shares of Intellia Therapeutics Inc (Symbol: NTLA) have crossed above the average analyst 12-month target price of $155.00, changing hands for $158.07/share. When a …

Website: https://www.nasdaq.com/articles/intellia-therapeutics-reaches-analyst-target-price-2021-08-24

Category: Contact NumberShow more

Hedge Funds Are Cashing Out Of Intellia Therapeutics, Inc

7 hours ago Finance.yahoo.com Get All

Intellia Therapeutics, Inc. (NASDAQ: NTLA) was in 29 hedge funds' portfolios at the end of the first quarter of 2021. The all time high for this statistic …

Website: https://finance.yahoo.com/news/hedge-funds-cashing-intellia-therapeutics-152847406.html

Category: Contact NumberShow more

How CRISPR Therapeutics is Competing Against Five Other

9 hours ago Halalinvestors.com Get All

Of the six companies, Intellia Therapeutics tops the list when it comes to the total number of drugs in the early stage of Investigational New Drug (IND)-enabling, with a total of 2. CRISPR Therapeutics, as well as Editas Medicine, Beam Therapeutics, Verve Therapeutics, and Graphite Bio, all have a drug each in the early IND-enabling stage.

Website: https://halalinvestors.com/insights/4ymtx0ksrxi9hnwsryiqrf/

Category: Contact NumberShow more

What Do Analysts Think Of Intellia Therapeutics Inc. (NTLA

3 hours ago Baxterreport.com Get All

The total number of common shares currently owned by the public is 68.16 million. NTLA does have institutional investors; and they hold 82.40% of the stock. Intellia Therapeutics Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 11 new insider purchases involving 110,785 shares.

Website: https://baxterreport.com/2021/09/01/what-do-analysts-think-of-intellia-therapeutics-inc-ntla/

Category: Contact NumberShow more

Is Intellia Therapeutics Stock a Buy? The Motley Fool

3 hours ago Fool.com Get All

Image Source: Getty Images. CRISPR's stock more than doubled last year while Editas' gained a respectable 27%. Intellia's stock bounced around throughout the year, eventually ending up …

Website: https://www.fool.com/investing/2020/01/05/is-intellia-therapeutics-stock-a-buy.aspx

Category: Contact NumberShow more

Intellia Therapeutics Announces Closing of $690 Million

9 hours ago Finance.yahoo.com Get All

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using

1. Author: Intellia Therapeutics, Inc.

Website: https://finance.yahoo.com/news/intellia-therapeutics-announces-closing-690-200100698.html

Category: Contact NumberShow more

Intellia Therapeutics, Inc. to Host Earnings Call

5 hours ago Finance.yahoo.com Get All

NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Intellia Therapeutics, Inc. (NASDAQ:NTLA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at

Website: https://finance.yahoo.com/news/intellia-therapeutics-inc-host-earnings-101500650.html

Category: Contact NumberShow more

Intellia Therapeutics Reaches Analyst Target Price Nasdaq

3 hours ago Nasdaq.com Get All

In recent trading, shares of Intellia Therapeutics Inc (Symbol: NTLA) have crossed above the average analyst 12-month target price of $82.82, changing hands for …

Website: https://www.nasdaq.com/articles/intellia-therapeutics-reaches-analyst-target-price-2021-06-11

Category: Contact NumberShow more

Intellia Therapeutics and CRISPR Therapeutics Announce U.S

3 hours ago Ir.crisprtx.com Get All

Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course.

Website: http://ir.crisprtx.com/news-releases/news-release-details/intellia-therapeutics-and-crispr-therapeutics-announce-us-patent/

Category: Contact NumberShow more

Intellia Therapeutics Inc.: Why Investors Shouldn’t Get

Just Now Marketingsentinel.com Get All

In the last trading session, 1.3 million shares of the Intellia Therapeutics Inc. (NASDAQ:NTLA) were traded, and its beta was 2.15. Most recently the company’s share price was $138.94, and it changed around $3.69 or 2.73% from the last close, which brings the market valuation of the company to $10

Website: https://marketingsentinel.com/2021/07/20/intellia-therapeutics-inc-why-investors-shouldnt-get-rid-of-ntla-stock-in-2021/

Category: Contact NumberShow more

The Intellia Therapeutics IPO Editas vs. Intellia Nanalyze

2 hours ago Nanalyze.com Get All

About Intellia Therapeutics. Founded in 2014, Intellia Therapeutics has taken in $89 million in funding compared to the $210 million in funding Editas Medicine (NASDAQ:EDIT) took in prior to their IPO. Intellia filed for an IPO last week to raise $50 million compared to the $94.4 million Editas Medicine raised in their recent IPO.

Website: https://www.nanalyze.com/2016/04/the-intellia-therapeutics-ipo-editas-vs-intellia/

Category: Contact NumberShow more

Intellia Therapeutics Success In Gene Therapy Leaps Ahead

3 hours ago Jgb7908.medium.com Get All

Intellia works on the development of ex vivo and in vivo therapies. In the case of NTLA-2001, it is believed the combination of in vivo administration, the two-part gene-editing system and mRNA technology could be a more effective way of developing and deploying gene therapy to a wider number

Website: https://jgb7908.medium.com/intellia-therapeutics-success-in-genetics-leaps-ahead-c7113c324b26

Category: Contact NumberShow more

Intellia Therapeutics Names James Basta, J.D., as

5 hours ago Finance.yahoo.com Get All

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9

Website: https://finance.yahoo.com/news/intellia-therapeutics-names-james-basta-113000012.html

Category: Contact NumberShow more

Intellia Therapeutics Announces Pricing of Public Offering

7 hours ago Marketwatch.com Get All

CAMBRIDGE, Jun 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing

Website: https://www.marketwatch.com/press-release/intellia-therapeutics-announces-pricing-of-public-offering-of-common-stock-2021-06-29

Category: Contact NumberShow more

Intellia Therapeutics Names James Basta, J.D., as

3 hours ago Benzinga.com Get All

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics

Website: https://www.benzinga.com/pressreleases/21/06/g21700879/intellia-therapeutics-names-james-basta-j-d-as-executive-vice-president-general-counsel-and-corpor

Category: Contact NumberShow more

PNC Financial Services Group and Intellia Therapeutics

7 hours ago Follow.health Get All

Cubist Systematic Strategies LLC‚Aos holdings in Intellia Therapeutics were worth $189,000 as of its most recent filing with the SEC. A number of other large …

Website: https://follow.health/linked/capital-firms/pnc-financial-services-group/pnc-financial-services-group-and-intellia-therapeutics/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of company is intellia therapeutics?

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system.

Who is eliana clark of intellia therapeutics?

Eliana Clark brings to Intellia nearly 20 years of experience in the biopharmaceutical industry.

Who is christine foster ceo of intellia therapeutics?

Christine Foster brings to Intellia a wealth of experience with more than 25 years under her belt in the pharmaceutical industry, both in biotech and large pharma.

Who is senior vice president of technical operations at intellia?

As Senior Vice President of Technical Operations at Intellia, Eliana is responsible for building out our manufacturing capabilities and CMC to support the necessary requirements for clinical trials and global regulatory filings.

Brand New Updated

Popular Brands

Intel
Icbc
Imcd
Iqvia
Isbank
Idex
Ing
Intuit
Itc
Ipg
Icade